NASDAQ$BLFS
BioLife Solutions Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
BioLife Solutions reported a decrease in revenue and gross margin for Q2 2023, while updating full year 2023 guidance and providing a pro forma financial profile excluding freezer business.
BioLife Solutions reported a decrease in total revenue by 3% to $39.5 million for the second quarter of 2023 compared to $40.5 million for the second quarter of 2022. The company is committed to divesting Stirling Ultracold and Custom Biogenic Systems by the end of 2023, focusing on higher margin streams and shareholder value.
- Total revenue for Q2 2023 was $39.5 million, a 3% decrease from Q2 2022.
- Cell Processing platform revenue increased by 22% to $18.7 million compared to the same period in 2022.
- Freezers and Thaw Systems platform revenue decreased by 26% to $13.9 million compared to the same period in 2022.
- The company is divesting its Stirling and CBS freezer assets to optimize the product portfolio.
Headline financials
Revenue & EPS history
BioLife · Revenue · Quarterly
$39.5M
Revenue by segment
BioLife · $18.7M total across 1 segment · Q2 2023
- Cell Processing platform$18.7M+21.4%100.0%
Forward guidance
BioLife Solutions updated its 2023 revenue guidance to a range of $144 million to $158 million, reflecting a year-over-year decrease of 11% to 2%.
Tailwinds
- Approvals of new cell and gene therapies
- Additional approvals of commercial CGT in new geographies
- Additional approvals of CGT in new indications
- Migration of commercial therapies to first or second-line treatment
- An eventual transition to allogeneic therapies
Headwinds
- Macro headwinds of global economic uncertainty causing reduced biotech spending across our customer base not only for capital equipment but also consumables.
- Cell processing revenue concentration and lumpiness
- Destocking by our largest direct customer compared to prior year period.
- Slowed growth from our largest distributor compared to prior period, caused by several of their downstream clinical customers having to complete validation of a new media product final container we introduced to mitigate supply chain shortages.
- Several clinical CGT customers’ reduced spending due to reduced clinical trial activity (trial early termination, pauses between phases and delayed patient enrollment).
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+4.3%
Avg return
30 days after
44%
22 / 50 earnings
Positive
+21.4%
Q3 2022
Best reaction
-34.5%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.3% | -2.4% | +22.4% | |
| Q4 2025 | +8.0% | -8.1% | -17.3% | |
| Q3 2025 | -4.2% | -4.1% | -5.8% | |
| Q2 2025 | +10.0% | +24.4% | +28.2% | |
| Q1 2025 | +4.0% | -1.4% | +6.0% | |
| Q4 2024 | +2.1% | +7.6% | -0.9% | |
| Q3 2024 | -9.4% | -21.0% | +0.5% | |
| Q2 2024 | +14.5% | +20.3% | +7.9% | |
| Q1 2024 | +8.9% | +25.0% | +13.2% | |
| Q4 2023 | +5.1% | -0.5% | +8.5% | |
| Q3 2023 | -5.7% | +3.1% | +14.2% | |
| Q2 2023 | -29.7% | -34.9% | -30.3% | |
| Q1 2023 | -2.9% | +3.5% | +20.6% | |
| Q4 2022 | +0.2% | +2.7% | -7.4% | |
| Q3 2022 | +21.4% | +14.1% | -4.6% | |
| Q2 2022 | +13.7% | +15.7% | +25.6% | |
| Q1 2022 | -3.8% | +1.6% | +18.3% | |
| Q4 2021 | -0.3% | +0.9% | -3.7% | |
| Q3 2021 | -6.0% | +5.2% | -30.3% | |
| Q2 2021 | -1.8% | -3.9% | +12.0% | |
| Q1 2021 | -2.1% | +4.8% | +25.1% | |
| Q4 2020 | +8.3% | -7.8% | -14.7% | |
| Q3 2020 | +5.8% | +0.8% | +21.6% | |
| Q2 2020 | +0.3% | -5.4% | +5.6% | |
| Q1 2020 | +3.0% | +10.5% | +1.5% | |
| Q4 2019 | -34.5% | -36.7% | -27.8% | |
| Q3 2019 | -12.8% | -8.8% | -7.4% | |
| Q2 2019 | -6.2% | +1.1% | +7.7% | |
| Q1 2019 | -2.4% | +4.5% | +8.8% | |
| Q4 2018 | +10.7% | +19.4% | +5.5% | |
| Q3 2018 | +15.0% | -8.0% | -7.8% | |
| Q2 2018 | -4.8% | -1.0% | +2.3% | |
| Q1 2018 | -3.7% | +7.6% | +23.5% | |
| Q4 2017 | -4.4% | -10.2% | +22.4% | |
| Q3 2017 | +18.0% | +21.6% | +8.2% | |
| Q2 2017 | +3.8% | +8.2% | +30.6% | |
| Q1 2017 | +3.7% | -1.4% | +7.8% | |
| Q4 2016 | -5.0% | -9.5% | -7.7% | |
| Q3 2016 | +0.7% | +2.7% | +5.4% | |
| Q2 2016 | -2.4% | -7.7% | -15.9% | |
| Q3 2012 | +10.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -14.3% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | -11.1% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro